Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04587-0
A study shows that integrating numerous multimodal, patient-level biomarkers enhances the prediction of cancer immunotherapy response, but generalizability is still a challenge.
Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04488-2
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04621-1
The International Consortium of Digital Twins in Healthcare and Medicine was established to advance medical digital twin technology as a new infrastructure for precision health.
Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w
In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.
Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04635-9
A 15-year cohort study shows that Alzheimer’s dementia risk is jointly shaped by Alzheimer’s pathology and cognitive resilience, with high resilience linked to lower risk, even under greater pathology.
Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04703-0
CRISP, a vision-based pathology foundation model developed exclusively from frozen section slides, supports treatment decision-making throughout the surgical workflow with superior performance to current foundation models and extensive validation, including in a prospective cohort.
Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04695-x
A suite of large pre-trained language models accurately extracts computable clinical data from unstructured electronic health records and integrates the findings into knowledge graphs that can facilitate understanding patient trajectories and treatment responses in the real world.
Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04596-z
An early assessment of the UK’s Our Future Health project shows how national-scale cohorts may reshape population medicine by accelerating discovery and clinical recruitment, provided that selection and phenotyping biases are carefully measured and managed.
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04678-y
Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04647-5
Consensus framework for the validation of generative AI: call for collaborators on the Validation Accords
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04685-z
As the availability of clinical trial data continues to lag behind, other forms of evidence generation leveraging real-world data and citizen science need to be considered to improve women’s health.
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04607-z
Following preclinical development, a randomized first-in-human trial showed that treatment with an inhaled, lung-epithelium-targeted siRNA directed against the receptor for advanced glycation end-products (RAGE) was safe and well tolerated and reduced RAGE levels in serum and bronchoalveolar lavage fluid.
Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04615-z
In a phase 2 randomized clinical trial, treatment with the myeloperoxidase (MPO) inhibitor mitiperstat, intended to target the neutrophil–MPO inflammatory pathway, did not improve symptoms or exercise function in individuals with heart failure with preserved or mildly reduced ejection fraction.
Nature Medicine, Published online: 08 September 2026; doi:10.1038/s41591-026-04641-x
A binding ban, and its limits: Japan legislates on heritable human genome editing
Nature Medicine, Published online: 07 September 2026; doi:10.1038/s41591-026-04633-x
The first generation of medical artificial intelligence (AI) was judged on whether algorithms could match clinicians. The next generation should be judged on whether carefully designed human–AI systems can improve patient outcomes.
Nature Medicine, Published online: 07 September 2026; doi:10.1038/s41591-026-04645-7
Strengthening clinical trial ethics and regulatory oversight in Africa: lessons from the TRACE initiative
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04401-x
Biobanks are introducing trusted research environments to enable secure data access, yet they can increase costs and complexity for biomedical researchers who use them. We discuss challenges and solutions and introduce the Python Phenofhy community tool for Our Future Health.
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04376-9
In a multicenter phase 2 trial, the fibroblast growth factor receptor inhibitor rogaratinib showed encouraging clinical efficacy in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors, suggesting a potential new treatment option for this patient population and demonstrating that an epigenetic mechanism of oncogene activation can be successfully targeted with a tyrosine kinase inhibitor.
Nature Medicine, Published online: 22 May 2026; doi:10.1038/s41591-026-04456-w
Naming in medicine: how disease nomenclature shapes diagnosis, research and patient lives
Nature Medicine, Published online: 22 May 2026; doi:10.1038/d41591-026-00027-1
A rare case of genomic integration of an adenovirus vector led to a child developing a tumor — successfully removed by surgery — which highlights the importance of long-term safety monitoring in patients who receive gene therapy.
Login